Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study
This study of 35442 HIV-infected people found that the incidence of lung cancer was 10-fold higher 5 years after smoking cessation compared with never smokers; the incidence of other smoking-related cancers returned to levels of nonsmokers 2-3 years after smoking cessation. Abstract Background Cance...
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2019-02, Vol.68 (4), p.650-657 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 657 |
|---|---|
| container_issue | 4 |
| container_start_page | 650 |
| container_title | Clinical infectious diseases |
| container_volume | 68 |
| creator | Shepherd, Leah Ryom, Lene Law, Matthew Petoumenos, Kathy Hatleberg, Camilla Ingrid d'Arminio Monforte, Antonella Sabin, Caroline Bower, Mark Bonnet, Fabrice Reiss, Peter de Wit, Stephane Pradier, Christian Weber, Rainer el-Sadr, Wafaa Lundgren, Jens Mocroft, Amanda |
| description | This study of 35442 HIV-infected people found that the incidence of lung cancer was 10-fold higher 5 years after smoking cessation compared with never smokers; the incidence of other smoking-related cancers returned to levels of nonsmokers 2-3 years after smoking cessation.
Abstract
Background
Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.
Methods
Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors.
Results
In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest |
| doi_str_mv | 10.1093/cid/ciy508 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2056763762</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/cid/ciy508</oup_id><sourcerecordid>2056763762</sourcerecordid><originalsourceid>FETCH-LOGICAL-c353t-730685a75ebb43796b28ea5797c9c8f4726fc177df86bf33bd6b98ce8e1040a93</originalsourceid><addsrcrecordid>eNp9kd2KFDEQhRtR3B-98QGkbgQRWpPOpJP2bujddQYWFHbd2yadrozR7mTMz8I8lm9o1lm99KKogvNxqqhTVa8oeU9Jxz5oO5U6cCKfVKeUM1G3vKNPy0y4rFeSyZPqLMbvhFAqCX9enTRdRxvG-Gn1q8cYVbLegTfQ250KmBLCzeJ_WLcD5SZI3xC2y17pBAXrldMYYOvKWiwjWAebvChXmCU7P6Gx2hblAHc25FhbZ1AnnOALhuhd_Ai3xfBCJQW9n-ei_dnuYD3dFwLh8h5dig_3rF2y9WZ7Bxch7yLcpDwdXlTPjJojvnzs59XXq8vbflNff_607dfXtWacpVow0kquBMdxXDHRtWMjUXHRCd1paVaiaY2mQkxGtqNhbJzasZMaJVKyIqpj59Xbo-8--J8ZYxoWGzXOs3LocxwawlvRMtE2BX13RHXwMQY0wz7YRYXDQMnwENFQfjUcIyrw60ffPC44_UP_ZlKAN0fA5_3_jH4DHFCbuQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2056763762</pqid></control><display><type>article</type><title>Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><creator>Shepherd, Leah ; Ryom, Lene ; Law, Matthew ; Petoumenos, Kathy ; Hatleberg, Camilla Ingrid ; d'Arminio Monforte, Antonella ; Sabin, Caroline ; Bower, Mark ; Bonnet, Fabrice ; Reiss, Peter ; de Wit, Stephane ; Pradier, Christian ; Weber, Rainer ; el-Sadr, Wafaa ; Lundgren, Jens ; Mocroft, Amanda</creator><creatorcontrib>Shepherd, Leah ; Ryom, Lene ; Law, Matthew ; Petoumenos, Kathy ; Hatleberg, Camilla Ingrid ; d'Arminio Monforte, Antonella ; Sabin, Caroline ; Bower, Mark ; Bonnet, Fabrice ; Reiss, Peter ; de Wit, Stephane ; Pradier, Christian ; Weber, Rainer ; el-Sadr, Wafaa ; Lundgren, Jens ; Mocroft, Amanda ; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group ; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</creatorcontrib><description>This study of 35442 HIV-infected people found that the incidence of lung cancer was 10-fold higher 5 years after smoking cessation compared with never smokers; the incidence of other smoking-related cancers returned to levels of nonsmokers 2-3 years after smoking cessation.
Abstract
Background
Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.
Methods
Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors.
Results
In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI}, 1.37-2.02]) and not significantly different from never smokers 1-1.9 years after cessation. Lung cancer incidence (n = 271) was elevated <1 year after cessation (aIRR, 19.08 [95% CI, 8.10-44.95]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]). Incidence of other smoking-related cancers (n = 622) was elevated in the first year after cessation (aIRR, 2.06 [95% CI, 1.42-2.99]) and declined to a level similar to nonsmokers thereafter.
Conclusions
Lung cancer incidence in HIV-infected individuals remained elevated >5 years after smoking cessation. Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduce future cancer risk.</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1093/cid/ciy508</identifier><identifier>PMID: 29912335</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Female ; HIV Infections - complications ; Humans ; Incidence ; Male ; Middle Aged ; Neoplasms - epidemiology ; Neoplasms - prevention & control ; Prospective Studies ; Smoking Cessation - statistics & numerical data</subject><ispartof>Clinical infectious diseases, 2019-02, Vol.68 (4), p.650-657</ispartof><rights>The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. 2018</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c353t-730685a75ebb43796b28ea5797c9c8f4726fc177df86bf33bd6b98ce8e1040a93</citedby><cites>FETCH-LOGICAL-c353t-730685a75ebb43796b28ea5797c9c8f4726fc177df86bf33bd6b98ce8e1040a93</cites><orcidid>0000-0001-8316-1122</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,1585,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29912335$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shepherd, Leah</creatorcontrib><creatorcontrib>Ryom, Lene</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Petoumenos, Kathy</creatorcontrib><creatorcontrib>Hatleberg, Camilla Ingrid</creatorcontrib><creatorcontrib>d'Arminio Monforte, Antonella</creatorcontrib><creatorcontrib>Sabin, Caroline</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Bonnet, Fabrice</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>de Wit, Stephane</creatorcontrib><creatorcontrib>Pradier, Christian</creatorcontrib><creatorcontrib>Weber, Rainer</creatorcontrib><creatorcontrib>el-Sadr, Wafaa</creatorcontrib><creatorcontrib>Lundgren, Jens</creatorcontrib><creatorcontrib>Mocroft, Amanda</creatorcontrib><creatorcontrib>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</creatorcontrib><creatorcontrib>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</creatorcontrib><title>Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study</title><title>Clinical infectious diseases</title><addtitle>Clin Infect Dis</addtitle><description>This study of 35442 HIV-infected people found that the incidence of lung cancer was 10-fold higher 5 years after smoking cessation compared with never smokers; the incidence of other smoking-related cancers returned to levels of nonsmokers 2-3 years after smoking cessation.
Abstract
Background
Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.
Methods
Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors.
Results
In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI}, 1.37-2.02]) and not significantly different from never smokers 1-1.9 years after cessation. Lung cancer incidence (n = 271) was elevated <1 year after cessation (aIRR, 19.08 [95% CI, 8.10-44.95]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]). Incidence of other smoking-related cancers (n = 622) was elevated in the first year after cessation (aIRR, 2.06 [95% CI, 1.42-2.99]) and declined to a level similar to nonsmokers thereafter.
Conclusions
Lung cancer incidence in HIV-infected individuals remained elevated >5 years after smoking cessation. Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduce future cancer risk.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Female</subject><subject>HIV Infections - complications</subject><subject>Humans</subject><subject>Incidence</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasms - epidemiology</subject><subject>Neoplasms - prevention & control</subject><subject>Prospective Studies</subject><subject>Smoking Cessation - statistics & numerical data</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kd2KFDEQhRtR3B-98QGkbgQRWpPOpJP2bujddQYWFHbd2yadrozR7mTMz8I8lm9o1lm99KKogvNxqqhTVa8oeU9Jxz5oO5U6cCKfVKeUM1G3vKNPy0y4rFeSyZPqLMbvhFAqCX9enTRdRxvG-Gn1q8cYVbLegTfQ250KmBLCzeJ_WLcD5SZI3xC2y17pBAXrldMYYOvKWiwjWAebvChXmCU7P6Gx2hblAHc25FhbZ1AnnOALhuhd_Ai3xfBCJQW9n-ei_dnuYD3dFwLh8h5dig_3rF2y9WZ7Bxch7yLcpDwdXlTPjJojvnzs59XXq8vbflNff_607dfXtWacpVow0kquBMdxXDHRtWMjUXHRCd1paVaiaY2mQkxGtqNhbJzasZMaJVKyIqpj59Xbo-8--J8ZYxoWGzXOs3LocxwawlvRMtE2BX13RHXwMQY0wz7YRYXDQMnwENFQfjUcIyrw60ffPC44_UP_ZlKAN0fA5_3_jH4DHFCbuQ</recordid><startdate>20190201</startdate><enddate>20190201</enddate><creator>Shepherd, Leah</creator><creator>Ryom, Lene</creator><creator>Law, Matthew</creator><creator>Petoumenos, Kathy</creator><creator>Hatleberg, Camilla Ingrid</creator><creator>d'Arminio Monforte, Antonella</creator><creator>Sabin, Caroline</creator><creator>Bower, Mark</creator><creator>Bonnet, Fabrice</creator><creator>Reiss, Peter</creator><creator>de Wit, Stephane</creator><creator>Pradier, Christian</creator><creator>Weber, Rainer</creator><creator>el-Sadr, Wafaa</creator><creator>Lundgren, Jens</creator><creator>Mocroft, Amanda</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8316-1122</orcidid></search><sort><creationdate>20190201</creationdate><title>Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study</title><author>Shepherd, Leah ; Ryom, Lene ; Law, Matthew ; Petoumenos, Kathy ; Hatleberg, Camilla Ingrid ; d'Arminio Monforte, Antonella ; Sabin, Caroline ; Bower, Mark ; Bonnet, Fabrice ; Reiss, Peter ; de Wit, Stephane ; Pradier, Christian ; Weber, Rainer ; el-Sadr, Wafaa ; Lundgren, Jens ; Mocroft, Amanda</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c353t-730685a75ebb43796b28ea5797c9c8f4726fc177df86bf33bd6b98ce8e1040a93</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Female</topic><topic>HIV Infections - complications</topic><topic>Humans</topic><topic>Incidence</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasms - epidemiology</topic><topic>Neoplasms - prevention & control</topic><topic>Prospective Studies</topic><topic>Smoking Cessation - statistics & numerical data</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shepherd, Leah</creatorcontrib><creatorcontrib>Ryom, Lene</creatorcontrib><creatorcontrib>Law, Matthew</creatorcontrib><creatorcontrib>Petoumenos, Kathy</creatorcontrib><creatorcontrib>Hatleberg, Camilla Ingrid</creatorcontrib><creatorcontrib>d'Arminio Monforte, Antonella</creatorcontrib><creatorcontrib>Sabin, Caroline</creatorcontrib><creatorcontrib>Bower, Mark</creatorcontrib><creatorcontrib>Bonnet, Fabrice</creatorcontrib><creatorcontrib>Reiss, Peter</creatorcontrib><creatorcontrib>de Wit, Stephane</creatorcontrib><creatorcontrib>Pradier, Christian</creatorcontrib><creatorcontrib>Weber, Rainer</creatorcontrib><creatorcontrib>el-Sadr, Wafaa</creatorcontrib><creatorcontrib>Lundgren, Jens</creatorcontrib><creatorcontrib>Mocroft, Amanda</creatorcontrib><creatorcontrib>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</creatorcontrib><creatorcontrib>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shepherd, Leah</au><au>Ryom, Lene</au><au>Law, Matthew</au><au>Petoumenos, Kathy</au><au>Hatleberg, Camilla Ingrid</au><au>d'Arminio Monforte, Antonella</au><au>Sabin, Caroline</au><au>Bower, Mark</au><au>Bonnet, Fabrice</au><au>Reiss, Peter</au><au>de Wit, Stephane</au><au>Pradier, Christian</au><au>Weber, Rainer</au><au>el-Sadr, Wafaa</au><au>Lundgren, Jens</au><au>Mocroft, Amanda</au><aucorp>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</aucorp><aucorp>Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study</atitle><jtitle>Clinical infectious diseases</jtitle><addtitle>Clin Infect Dis</addtitle><date>2019-02-01</date><risdate>2019</risdate><volume>68</volume><issue>4</issue><spage>650</spage><epage>657</epage><pages>650-657</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><abstract>This study of 35442 HIV-infected people found that the incidence of lung cancer was 10-fold higher 5 years after smoking cessation compared with never smokers; the incidence of other smoking-related cancers returned to levels of nonsmokers 2-3 years after smoking cessation.
Abstract
Background
Cancers are a major source of morbidity and mortality for human immunodeficiency virus (HIV)-infected persons, but the clinical benefits of smoking cessation are unknown.
Methods
Participants were followed from 1 January 2004 until first cancer diagnosis, death, or 1 February 2016. Smoking status was defined as ex-smoker, current smoker, and never smoker. Adjusted incidence rate ratios (aIRRs) were calculated using Poisson regression, adjusting for demographic and clinical factors.
Results
In total 35442 persons from the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study contributed 309803 person-years of follow-up. At baseline, 49% were current smokers, 21% were ex-smokers, and 30% had never smoked. Incidence of all cancers combined (n = 2183) was highest <1 year after smoking cessation compared to never smokers (aIRR, 1.66 [95% confidence interval {CI}, 1.37-2.02]) and not significantly different from never smokers 1-1.9 years after cessation. Lung cancer incidence (n = 271) was elevated <1 year after cessation (aIRR, 19.08 [95% CI, 8.10-44.95]) and remained 8-fold higher 5 years after smoking cessation (aIRR, 8.69 [95% CI, 3.40-22.18]). Incidence of other smoking-related cancers (n = 622) was elevated in the first year after cessation (aIRR, 2.06 [95% CI, 1.42-2.99]) and declined to a level similar to nonsmokers thereafter.
Conclusions
Lung cancer incidence in HIV-infected individuals remained elevated >5 years after smoking cessation. Deterring uptake of smoking and smoking cessation efforts should be prioritised to reduce future cancer risk.</abstract><cop>US</cop><pub>Oxford University Press</pub><pmid>29912335</pmid><doi>10.1093/cid/ciy508</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-8316-1122</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2019-02, Vol.68 (4), p.650-657 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2056763762 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection |
| subjects | Adult Aged Aged, 80 and over Female HIV Infections - complications Humans Incidence Male Middle Aged Neoplasms - epidemiology Neoplasms - prevention & control Prospective Studies Smoking Cessation - statistics & numerical data |
| title | Cessation of Cigarette Smoking and the Impact on Cancer Incidence in Human Immunodeficiency Virus-infected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T08%3A05%3A13IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cessation%20of%20Cigarette%20Smoking%20and%20the%20Impact%20on%20Cancer%20Incidence%20in%20Human%20Immunodeficiency%20Virus-infected%20Persons:%20The%20Data%20Collection%20on%20Adverse%20Events%20of%20Anti-HIV%20Drugs%20Study&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Shepherd,%20Leah&rft.aucorp=Data%20Collection%20on%20Adverse%20Events%20of%20Anti-HIV%20Drugs%20(D:A:D)%20Study%20Group&rft.date=2019-02-01&rft.volume=68&rft.issue=4&rft.spage=650&rft.epage=657&rft.pages=650-657&rft.issn=1058-4838&rft.eissn=1537-6591&rft_id=info:doi/10.1093/cid/ciy508&rft_dat=%3Cproquest_cross%3E2056763762%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2056763762&rft_id=info:pmid/29912335&rft_oup_id=10.1093/cid/ciy508&rfr_iscdi=true |